323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Appoints Jeff Knight as Chief Development and Operating Officer
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Announces Pricing of Underwritten Offering
New Data Demonstrate CD47 Expression Level Helps Predict Response to Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
ALX Oncology Increases Shares Under 2025 Inducement Plan by 1.3 Million
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
SC TO-I
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Amended Tender Offer Statement by Issuer
Schedule 13G - Ownership Report